Drug intelligence / Profile preview

camrelizumab + albumin paclitaxel + nedaplatin + apatinib

Development stage: Unknown
Lead developer: Hengrui Pharmaceutical
Modality: Nanoparticles → Drug Delivery Systems, Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous, Oral

Overview

This neoadjuvant combination regimen consists of the PD-1 inhibitor camrelizumab, the chemotherapy agents albumin paclitaxel and nedaplatin, and the VEGFR-2 tyrosine kinase inhibitor apatinib. It is being investigated by the Second Affiliated Hospital, School of Medicine, Zhejiang University for the treatment of resectable esophageal squamous cell carcinoma (ESCC). Camrelizumab is a humanized monoclonal antibody that blocks the interaction between PD-1 and its ligands, thereby restoring T-cell antitumor activity. Apatinib is a small molecule that selectively inhibits VEGFR-2, suppressing tumor angiogenesis. The chemotherapy components, albumin paclitaxel and nedaplatin, provide cytotoxic effects by stabilizing microtubules and cross-linking DNA, respectively. This multi-modal approach aims to increase the pathological complete response (pCR) rate and improve surgical outcomes in locally advanced ESCC.

Brand names: CamrelizumabAiRuiKaAiTanAbraxane
Other names: CarrelizumabCarillizumabCarrillizumabSHR-1210 + Albumin Paclitaxel + Nedaplatin + Apatinib

Targets

VEGFR2 (Vascular endothelial growth factor receptor 2)PDCD1 (Programmed cell death protein 1 receptor)DNATUBB (Tubulin (alpha and beta subunits))

Beyond the preview

Go deeper on camrelizumab + albumin paclitaxel + nedaplatin + apatinib.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on camrelizumab + albumin paclitaxel + nedaplatin + apatinib.

Explore the full profile